IPCure envisions leveraging the recently unified concepts of inflammation and Regulated Cell Death to achieve groundbreaking advancements in medical science. By selectively controlling key enzymes such as Caspase-2, -1, and -4 through next-generation rational design, we aspire to develop solutions that address neuro-degenerative, inflammatory, and metabolic diseases. Our flagship candidate targets Caspase-2, a crucial enzyme in memory function, aiming to revolutionize the treatment of Frontotemporal Dementia (FTD) and Alzheimer's Disease (AD).

Through cutting-edge research and development, IPCure is committed to transforming therapeutic options and improving patient outcomes. Our ultimate goal is to provide innovative, effective treatments that pave the way toward the cure of these debilitating conditions, enhancing the quality of life for patients worldwide.